Affymax Reports Second Quarter 2012 Financial Results

Conference Call with Management Today

Management will host a teleconference and webcast to provide a general business overview, as well as to discuss second quarter 2012 financial results today, August 8, 2012, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

Interested parties can listen to the live teleconference by dialing [phone] from the U.S. or [phone] for international callers. Individuals may access the live audio webcast by visiting: http://www.investors.affymax.com/events.cfm. A replay of the webcast will be available on the Company's website for 30 days following the live event.

About Affymax, Inc.

Affymax, Inc. is a biopharmaceutical company based in Palo Alto, California. Affymax's mission is to discover, develop and deliver innovative therapies that improve the lives of patients with kidney disease and other serious and often life-threatening illnesses.

The company's first marketed product, OMONTYS ^® (peginesatide) Injection, was approved by the U.S. Food and Drug Administration (FDA) in March 2012. For additional information, please visit www.affymax.com.

This release contains forward-looking statements, including statements regarding financial projections and condition, the continuation and success of the Company’s collaboration with Takeda and the commercialization of OMONTYS. The Company’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties, including risks relating to factors affecting the commercial potential of OMONTYS, the continued safety and efficacy of OMONTYS, industry and competitive environment, regulatory requirements by the FDA or other regulatory authorities, including post-marketing studies, trials and Risk Evaluation and Mitigation Strategy, potential for disruptions to supply, financing requirements and ability to access capital, and other matters that are described in Affymax’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement in this press release.

AFFYMAX, INC.
CONDENSED BALANCE SHEETS
(in thousands, except share data)
			June 30,			December 31,
			2012			2011
			(Unaudited)
Assets
Current assets
Cash and cash equivalents		$	88,734		$	54,339
Short-term investments			29,342			44,165
Receivable from Takeda			3,230			6,937
Inventory			2,040			—
Deferred tax assets			351			351
Prepaid expenses and other current assets			5,332			1,828
Total current assets			129,029			107,620
Property and equipment, net			3,186			3,013
Restricted cash			1,135			1,135
Deferred tax assets, net of current			6,888			6,888
Other assets			3,729			339
Total assets		$	143,967		$	118,995
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable		$	3,050		$	941
Accrued liabilities			11,801			13,733
Accrued clinical trial expenses			2,150			3,365
Deposit from Takeda			6,143			1,998
Notes payable, current			1,823			—
Total current liabilities			24,967			20,037
Long-term income tax liability			10,479			10,411
Advance from Takeda			10,263			6,121
Deferred revenue			5,174			5,174
Notes payable, net of current			8,177			—
Other long-term liabilities			818			1,255
Total liabilities			59,878			42,998
Commitments and contingencies
Stockholders’ equity
Common stock: $0.001 par value, 100,000,000 shares authorized, 36,146,356 and 35,733,181 shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively			36			36
Additional paid-in capital			534,854			526,244
Accumulated deficit			(450,804	)		(450,301	)
Accumulated other comprehensive income			3			18
Total stockholders’ equity			84,089			75,997
Total liabilities and stockholders’ equity		$	143,967		$	118,995

AFFYMAX, INC.
CONDENSED STATEMENTS OF COMPREHENSIVE LOSS
(in thousands, except per share data)
(Unaudited)
		Three Months Ended June 30,								Six Months Ended June 30,
			2012				2011				2012				2011
Revenue:
Collaboration revenue		$	2,754			$	14,146			$	65,959			$	30,825
License and royalty revenue			1				5				5				9
Total revenue			2,755				14,151				65,964				30,834
Operating expenses:
Research and development			12,963				18,594				29,070				36,743
Selling, general and administrative			21,173				8,088				36,755				16,254
Total operating expenses			34,136				26,682				65,825				52,997
Income (loss) from operations			(31,381	)			(12,531	)			139				(22,163	)
Interest income			20				47				33				91
Interest expense			(591	)			(37	)			(648	)			(73	)
Other income (expense), net			(4	)			2				(26	)			36
Net loss before provision for income taxes			(31,956	)			(12,519	)			(502	)			(22,109	)
Provision for income taxes			—				—				1				1
Net loss		$	(31,956	)		$	(12,519	)		$	(503	)		$	(22,110	)
Net income (loss) per share:
Basic and diluted		$	(0.89	)		$	(0.35	)		$	(0.01	)		$	(0.72	)
Weighted-average number of shares used in computing basic and diluted net loss per share			36,075				35,388				35,924				30,896
Total comprehensive loss		$	(31,961	)		$	(12,488	)		$	(517	)		$	(22,071	)

AFFYMAX, INC.
COLLABORATION REVENUE
(in thousands)
		Three Months Ended June 30,						Six Months Ended June 30,
		2012			2011			2012			2011
Revenue recognized under CAPM		$	—		$	9,926		$	—		$	26,606
Net expense reimbursement after CAPM			2,754			4,220			7,959			4,219
Milestone payments			—			—			58,000			—
Total collaboration revenue		$	2,754		$	14,146		$	65,959		$	30,825

(1)		Revenue recognized for the three and six months ended June 30, 2011, consists primarily of amounts received from Takeda under our collaboration agreement, including upfront payments, development milestones, Takeda’s purchase of active pharmaceutical ingredient, or API, and reimbursement of development expenses. Revenue for these payments was recognized under the Contingency Adjusted Performance Model, or CAPM, of revenue recognition, under which all such amounts were deferred and recognized ratably over the expected development period, which ended in May 2011 with the submission of the NDA for OMONTYS to the FDA.

« First ‹ Previous 1 2 3 Next › Last »